Kalaris Therapeutics Inc
KLRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $108 | $50 | $33 | $46 |
| - Cash | $42 | $88 | $101 | $118 |
| + Debt | $2 | $0 | $0 | $0 |
| Enterprise Value | $67 | -$38 | -$68 | -$73 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12 | -$11 | -$9 | -$18 |
| % Margin | – | – | – | – |
| Net Income | -$12 | -$11 | -$10 | -$18 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.64 | -0.61 | -2.52 | -3.64 |
| % Growth | -4.9% | 75.8% | 30.8% | – |
| Operating Cash Flow | -$11 | -$15 | -$7 | – |
| Capital Expenditures | -$0 | $0 | $0 | – |
| Free Cash Flow | -$12 | -$15 | -$7 | – |